Congress Adopts New User Fee Program

July 2, 2002

Jill Wechsler

Jill Wechsler

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Pharmaceutical Technology, Pharmaceutical Technology-07-02-2002, Volume 26, Issue 7

To fund expanded FDA operations designed to streamline drug development and approval, FDA and industry representatives have negotiated the Prescription Drug User Fee Act III.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-07-02-2002

FDA Recommends Pausing Use of J&J COVID-19 Vaccine After Reports of Blood Clots

FDA Inspectors Cited Critical Problems at Emergent Facility

Focusing on Accelerated Formulation Strategies